Recruitment Completed in Estelle® Population PK Substudy

  • Study to determine impact of demographic characteristics on the absorption, distribution and excretion of Estelle®
  • PK study is part of the Estelle® Phase III program in the US/Canada, which remains on track to report top line results in Q1 2019

Liège, Belgium, 09 August 2017– Mithra (Euronext Brussels: MITRA), a company specialized in Women’s Health, today announces that it has completed recruitment in the population PK substudy for Estelle®. This trial is part of the Estelle® Phase III E4 Freedom program currently ongoing in Europe/Russia and in the US/Canada, with results expected in Q3 2018 and Q1 2019, respectively. Estelle® is Mithra’s combined oral contraceptive (COC) candidate composed of 15 mg Estetrol (E4) and 3 mg drospirenone (DRSP).